Education
About Us
Working with TipRanks
Follow Us
Lynx1 Capital Management LP Insider Profile
11 Followers
Lynx1 Capital Management LP, Ten Percent Owner at TScan Therapeutics, holds 591.70K shares in Passage Bio (Ticker: PASG), holds 7.95M shares in TScan Therapeutics (Ticker: TCRX). Most recently, Lynx1 Capital Management LP Bought ― shares of Passage Bio on Jul 24, 2025 for an estimated value of 733.53K.
Lynx1 Capital Management LP TScan Therapeutics (TCRX)Ten Percent Owner
TScan Therapeutics (TCRX)
Ten Percent Owner
Ranked #98,112 out of 102,596 Corporate Insiders
Profitable Transactions
1 out of 6 Profitable Transactions
Average Return
-61.90%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Lynx1 Capital Management LP holds in companies
Most Profitable Insider Trade
The most profitable trade made by Lynx1 Capital Management LP
Lynx1 Capital Management LP's Trading History
TScan Therapeutics
May 21, 2025
Ten Percent Owner
Informative Buy
3.11M
$15.34M
Passage Bio
Jul 24, 2025
Ten Percent Owner
Informative Buy
733.53K
$4.40M
List of latest transactions for each holding click on a transaction to see Lynx1 Capital Management LP's performance on stock
You May Also Like
Lynx1 Capital Management LP insider profile FAQ
What is the percentage of profitable transactions made by Lynx1 Capital Management LP?
The percentage of profitable transactions made by Lynx1 Capital Management LP is 17%.
What is the average return per transaction made by Lynx1 Capital Management LP?
The average return per transaction made by Lynx1 Capital Management LP is -61.90%.
What stocks does Lynx1 Capital Management LP hold?
Lynx1 Capital Management LP holds: TCRX, PASG stocks.
What was Lynx1 Capital Management LP’s latest transaction?
Lynx1 Capital Management LP latest transaction was an Informative Buy of $733.53K.
What was Lynx1 Capital Management LP's most profitable transaction?
Lynx1 Capital Management LP’s most profitable transaction was an Informative Buy of TCRX stock on May 21, 2025. The return on the trade was 37.80%.
What is Lynx1 Capital Management LP's role in TScan Therapeutics?
Lynx1 Capital Management LP's role in TScan Therapeutics is Ten Percent Owner.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.